ALKS 4510

ALKS 4510 is an investigational, orally administered, small molecule agonist of the orexin 2 receptor, developed by Alkermes for central nervous system disorders. It is currently being evaluated in first-in-human phase 1 studies assessing its safety, tolerability, and pharmacokinetics in healthy adult volunteers. ALKS 4510 is part of Alkermes' broader orexin agonist program and is anticipated to enter further clinical development targeting sleep and neuropsychiatric disorders. The precise clinical indications beyond CNS disorders have not yet been disclosed for this agent, but orexin 2 receptor agonists are being explored for conditions such as narcolepsy and idiopathic hypersomnia[1][3][4][5][6][9].